On March 12, 2024, SciSparc Ltd. reported progress from its venture MitoCareX, highlighting the identification of potential anti-cancer treatments through virtual molecule screening. MitoCareX is also developing a predictive AI model to enhance drug discovery targeting the SLC25 protein family.